Oclacitinib 10 years later: lessons learned and directions for the future

Area of Science:

• Veterinary Dermatology
• Immunology
• Pharmacology

Background:

• Oclacitinib has been available for canine atopic dermatitis (AD) and allergic skin disease for 10 years.
• Extensive literature exists on its efficacy and safety in dogs, including off-label uses.
• Clinician and owner concerns persist regarding long-term oclacitinib safety.

Approach:

• This review synthesizes published evidence on oclacitinib's efficacy and safety.
• It examines the drug's speed of action and effects on the canine immune system.
• The review summarizes 10 years of clinical experience and suggests future research directions.

Key Points:

• Oclacitinib demonstrates efficacy in managing canine atopic dermatitis and allergic skin disease.
• Evidence supports its use at labeled doses and explores off-label applications.
• Understanding its immunomodulatory effects and long-term safety profile is crucial.

Conclusions:

• A decade of research provides a robust understanding of oclacitinib's benefits and risks.
• Further studies are needed to address long-term safety concerns and optimize its use.
• Future directions include exploring novel applications and refining treatment protocols for canine allergic skin conditions.